0001558370-21-015302.txt : 20211109 0001558370-21-015302.hdr.sgml : 20211109 20211109161721 ACCESSION NUMBER: 0001558370-21-015302 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20211109 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211109 DATE AS OF CHANGE: 20211109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AGILITI, INC. \DE CENTRAL INDEX KEY: 0001749704 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISCELLANEOUS EQUIPMENT RENTAL & LEASING [7350] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40361 FILM NUMBER: 211392444 BUSINESS ADDRESS: STREET 1: 6625 WEST 78TH STREET, SUITE 300 CITY: MINNEAPOLIS STATE: MN ZIP: 55439 BUSINESS PHONE: 617-227-1050 MAIL ADDRESS: STREET 1: 6625 WEST 78TH STREET, SUITE 300 CITY: MINNEAPOLIS STATE: MN ZIP: 55439 8-K 1 agti-20211109x8k.htm 8-K
AGILITI, INC. \DE0001749704false00017497042021-11-092021-11-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 9, 2021

AGILITI, INC.

(Exact name of Registrant as specified in its charter)

Delaware

    

001-40361

    

83-1608463

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

6625 West 78th Street, Suite 300

Minneapolis, MN 55439

(Address of principal executive offices, including zip code)

(952) 893-3200

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, par value $0.0001

AGTI

The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02. Results of Operations and Financial Condition.

On November 9, 2021, Agiliti, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2021. A copy of the press release attached hereto as Exhibit 99.1, and is incorporated herein by reference.

The information in this Current Report, including the exhibit attached hereto as Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such disclosure in this Form 8-K in such a filing.

Item 9.01. Financial Statements and Exhibits.

Exhibit
Number

    

Description

99.1

Press Release dated November 9, 2021.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 9, 2021

AGILITI, INC.

By:

/s/ James B. Pekarek

Name:

James B. Pekarek

Title:

Executive Vice President and Chief Financial Officer

EX-99.1 2 agti-20211109xex99d1.htm EX-99.1

AGILITI ANNOUNCES FINANCIAL RESULTS FOR THIRD QUARTER 2021
AND RAISES FULL YEAR 2021 GUIDANCE

Minneapolis, Minn.--(BUSINESS WIRE)— November 9, 2021 – Agiliti Inc. (NYSE: AGTI) (“Agiliti”), a nationwide provider of healthcare technology management and service solutions to the United States healthcare industry, today announced its financial results for the quarter ended September 30, 2021, and raised its full-year guidance for 2021.

Third Quarter 2021 Highlights

Revenue growth of 35 percent year-over-year to $262 million
Net income of $9.7 million, up $19.9 million from the prior year period, and diluted income per share of $0.07, up $0.17 per share from the prior year period
Adjusted EBITDA1 growth of 46 percent year-over-year to $82 million, and adjusted diluted earnings per share of $0.23, up $0.10 per share from the prior year period
Total debt of $1,044.4 million; Net debt1 of $920.7 million; Net Leverage ratio1 further reduced to 2.9x
Raised full year 2021 guidance with expected revenue of $1,010-1,020 million and Adjusted EBITDA of $300-310 million2

Our strong results from the quarter and our increased financial guidance for the year reflect the powerful fundamentals of our business” said Tom Leonard, Chief Executive Officer. “Agiliti’s nationwide maintenance and logistics infrastructure places us within the local community of the healthcare providers we serve each day.  This same operations network is now supporting our recent acquisitions, with a unique and differentiated value proposition for our customers, delivered though our local service teams.”

Third Quarter and Year-to-Date 2021 Financial Results

Total revenue for the three months ended September 30, 2021, was $262.4 million, representing a 34.8 percent increase from total revenue of $194.7 million for the same period of 2020. Total revenue for the nine months ended September 30, 2021, was $748.2 million, representing a 33.8 percent increase from total revenue of $559.1 million for the same period of 2020.

Net income for the three months ended September 30, 2021, was $9.7 million compared to a net loss of $10.2 million for the same period of 2020. Net income for the nine months ended September 30, 2021, was $14.0 million, representing a $36.0 million increase compared to a net loss of $22.0 million for the same period of 2020.

Adjusted EBITDA for the three months ended September 30, 2021, was $81.9 million, a 46.2 percent increase from Adjusted EBITDA of $56.1 million for the same period of 2020. Adjusted EBITDA for the nine months ended September 30, 2021, was $245.8 million, a 51.6 percent increase from Adjusted EBITDA of $162.2 million for same period of 2020.

Subsequent Events

On October 1, 2021, Agiliti completed its acquisition of Sizewise Rentals, Inc., (“Sizewise”), a manufacturer and distributor of specialty hospital beds, surfaces and patient handling equipment. The transaction was financed with a combination of cash on hand as well as an incremental $150M Term Loan B (fungible with the existing 0% LIBOR floor tranche). The combination enables Agiliti to broaden its portfolio and clinical expertise within the growing specialty equipment services market, expand its total addressable market opportunity and target meaningful growth and cost reduction synergies.


2021 Financial Outlook

For the full year 2021, the Company now expects revenue to be in the range of $1,010 million to $1,020 million, an increase from the prior range of $965 million to $980 million, representing growth of 31 to 32 percent. In addition, the Company now expects Adjusted EBITDA to be in the range of $300 million to $310 million, an increase from the prior range of $280 million to $290 million, representing growth of 28 to 31 percent. Finally, the Company expects capital expenditures for 2021 to be in the range of $67 million to $72 million, an increase from the prior range of $65 million to $70 million. Capex as a percentage of revenue is expected to remain in the range of 6 to 7 percent.

Conference Call Information

Agiliti will hold a conference call to discuss its 2021 third quarter results on Tuesday, November 9, at 5 p.m. Eastern Time (4 p.m. Central Time).

The conference call can be accessed live over the phone by dialing 1-877-300-8521 or for international callers, 1-412-317-6026. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 10160759. The replay will be available until November 16, 2021.

Interested investors and other parties may view a simultaneous webcast of the conference call by visiting the Agiliti Investor Relations site at https://investors.agilitihealth.com. The webcast replay will be available for a limited time shortly following the call.

About Agiliti

Agiliti is an essential service provider to the U.S. healthcare industry with solutions that help support a more efficient, safe and sustainable healthcare delivery system. Agiliti serves more than 9,000 national, regional and local acute care and alternate site providers across the U.S. For more than eight decades, Agiliti has delivered medical equipment management and service solutions that help healthcare providers reduce costs, increase operating efficiencies and support optimal patient outcomes.


CONTACT:

Kate Kaiser

Corporate Communication and Investor Relations

kate.kaiser@agilitihealth.com


Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Agiliti Inc., believes statements in this presentation looking forward in time, including preliminary results, involve risks and uncertainties. The following factors, among others, could adversely affect our business, operations and financial condition causing our actual results to differ materially from those expressed in any forward-looking statements: our history of net losses and substantial interest expense; our need for substantial cash to operate and expand our business as planned; our substantial outstanding debt and debt service obligations; restrictions imposed by the terms of our debt; a decrease in the number of patients our customers are serving; our ability to effect change in the manner in which health care providers traditionally procure medical equipment; the absence of long-term commitments with customers; our ability to renew contracts with group purchasing organizations and integrated delivery networks; changes in reimbursement rates and policies by third-party payors; the impact of health care reform initiatives; the impact of significant regulation of the health care industry and the need to comply with those regulations; the effect of prolonged negative changes in domestic and global economic conditions; difficulties or delays in our continued expansion into certain of our businesses/geographic markets and developments of new businesses/geographic markets; additional credit risks in increasing business with home care providers and nursing homes, impacts of equipment product recalls or obsolescence; increases in vendor costs that cannot be passed through to our customers; and other Risk Factors as detailed in our final prospectus filed with the Securities and Exchange Commission (“SEC”), on April 26, 2021, and our quarterly reports on Form 10-Q.

----------------------------

1 Non-GAAP Measures. See further discussion below.

2 With regard to the non-GAAP Adjusted EBITDA guidance provided above, a reconciliation to GAAP net income has not been provided as the quantification of certain items included in the calculation of GAAP net income cannot be calculated or predicted at this time without unreasonable efforts. For example, the non-GAAP adjustment for stock-based compensation expense requires additional inputs such as number of shares granted and market price that are not currently ascertainable, and the non-GAAP adjustment for certain reserves and expenses depends on the timing and magnitude of these expenses and cannot be accurately forecasted. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could have a potentially unpredictable, and potentially significant, impact on its future GAAP financial results.


Agiliti, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(in thousands, except share and per share information)

(unaudited)

Three Months Ended

Nine Months Ended

September 30,

September 30,

    

2021

    

2020

    

2021

    

2020

    

    

Revenue

$

262,424

$

194,721

$

748,212

$

559,121

Cost of revenue

 

158,990

 

120,115

 

444,346

 

359,239

Gross margin

 

103,434

 

74,606

 

303,866

 

199,882

Selling, general and administrative

 

75,052

 

71,732

 

225,334

 

180,838

Operating income

 

28,382

 

2,874

 

78,532

 

19,044

Loss on extinguishment of debt

10,116

Interest expense

 

10,711

 

13,560

 

40,444

 

46,532

Income (loss) before income taxes and noncontrolling interest

 

17,671

 

(10,686)

 

27,972

 

(27,488)

Income tax expense (benefit)

 

7,943

 

(573)

 

13,832

 

(5,678)

Consolidated net income (loss)

 

9,728

 

(10,113)

 

14,140

 

(21,810)

Net income attributable to noncontrolling interest

 

60

 

95

 

117

 

198

Net income (loss) attributable to Agiliti, Inc. and Subsidiaries

$

9,668

$

(10,208)

$

14,023

$

(22,008)

Basic income (loss) per share

$

0.07

$

(0.10)

$

0.12

$

(0.22)

Diluted income (loss) per share

$

0.07

$

(0.10)

$

0.11

$

(0.22)

Weighted-average common shares outstanding:

Basic

130,380,551

98,983,296

117,578,750

98,973,853

Diluted

138,490,526

98,983,296

125,515,000

98,973,853


Agiliti, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in thousands, except share and per share information)

(unaudited)

    

September 30,

    

December 31,

2021

2020

Assets

Current assets:

Cash and cash equivalents

$

123,713

$

206,505

Accounts receivable, less allowance for doubtful accounts of $2,500 at September 30, 2021 and $1,993 at December 31, 2020

200,779

154,625

Inventories

 

29,092

 

27,062

Other current assets

 

14,847

 

14,175

Total current assets

 

368,431

 

402,367

Property and equipment:

Medical equipment

 

301,189

 

285,723

Property and office equipment

 

140,138

 

112,646

Accumulated depreciation

 

(251,530)

 

(183,953)

Total property and equipment, net

 

189,797

 

214,416

Other long-term assets:

Goodwill

 

1,122,530

 

817,113

Operating lease right-of-use assets

56,692

51,214

Other intangibles, net

 

528,119

 

402,095

Other

 

18,884

 

16,151

Total assets

$

2,284,453

$

1,903,356

Liabilities and Equity

Current liabilities:

Current portion of long-term debt

$

15,849

$

16,044

Current portion of operating lease liability

15,607

14,155

Current portion of obligation under tax receivable agreement

15,691

15,572

Accounts payable

 

48,712

 

37,215

Accrued compensation

 

37,658

 

38,671

Accrued interest

 

2,784

 

6,347

Deferred revenue

6,858

8,800

Other accrued expenses

 

24,111

 

22,727

Total current liabilities

 

167,270

 

159,531

Long-term debt, less current portion

 

1,028,626

 

1,145,055

Obligation under tax receivable agreement, pension and other long-term liabilities

 

57,216

 

53,794

Operating lease liability, less current portion

45,919

40,283

Deferred income taxes, net

 

109,469

 

62,748

Commitments and contingencies (Note 11)

Equity

Common stock, $0.0001 par value; 350,000,000 shares authorized; 130,389,758 and 98,983,296 shares issued and outstanding at September 30, 2021 and December 31, 2020

 

13

 

10

Additional paid-in capital

 

932,867

 

513,902

Accumulated deficit

 

(54,469)

 

(68,492)

Accumulated other comprehensive loss

 

(2,581)

 

(3,619)

Total Agiliti, Inc. and Subsidiaries equity

 

875,830

 

441,801

Noncontrolling interest

 

123

 

144

Total equity

 

875,953

 

441,945

Total liabilities and equity

$

2,284,453

$

1,903,356


Agiliti, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

Nine Months Ended

September 30,

    

2021

    

2020

    

Cash flows from operating activities:

Consolidated net income (loss)

$

14,140

$

(21,810)

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

Depreciation

 

78,249

 

72,955

Amortization

 

63,482

 

54,536

Remeasurement of tax receivable agreement and contingent consideration

4,542

 

8,231

Loss on extinguishment of debt

7,716

Provision for doubtful accounts

 

1,121

 

1,336

Provision for inventory obsolescence

 

2,539

 

458

Non-cash share-based compensation expense

 

10,127

 

7,657

Gain on sales and disposals of equipment

 

(3,939)

 

(852)

Deferred income taxes

 

12,040

 

(5,967)

Changes in operating assets and liabilities:

Accounts receivable

 

(30,305)

 

(37,618)

Inventories

 

1,241

 

(5,534)

Other operating assets

 

(5,392)

 

(6,431)

Accounts payable

 

4,701

 

(1,138)

Other operating liabilities

 

(21,849)

 

33,903

Net cash provided by operating activities

 

138,413

 

99,726

Cash flows from investing activities:

Medical equipment purchases

 

(23,912)

 

(22,806)

Property and office equipment purchases

 

(15,539)

 

(15,465)

Proceeds from disposition of property and equipment

 

8,187

 

2,157

Acquisitions, net of cash acquired

(450,198)

(89,706)

Net cash used in investing activities

 

(481,462)

 

(125,820)

Cash flows from financing activities:

Proceeds under revolver

35,000

249,500

Payments under revolver

(35,000)

(283,000)

Proceeds under term loan

198,052

124,844

Payments under term loan

(326,770)

(5,895)

Payments of principal under finance lease liability

 

(6,721)

 

(6,312)

Payments of deferred financing costs

(229)

(199)

Payments under tax receivable agreement

(748)

Distributions to noncontrolling interests

 

(138)

 

(322)

Proceeds from exercise of stock options

380

Dividend and equity distribution payment

(926)

(1,138)

Proceeds from issuance of common stock

401,441

Stock issuance costs

(4,084)

Shares forfeited for taxes

(145)

Change in book overdrafts

 

 

(1,771)

Net cash provided by financing activities

 

260,257

 

75,562

Net change in cash and cash equivalents

 

(82,792)

 

49,468

Cash and cash equivalents at the beginning of period

 

206,505

 

Cash and cash equivalents at the end of period

$

123,713

$

49,468

Supplemental cash flow information:

Interest paid

$

40,991

$

41,279

Income taxes paid

 

2,647

 

1,007


Use of non-GAAP information

This press release contains non-GAAP measures, including EBITDA, Adjusted EBITDA, Adjusted EPS and Net Leverage Ratio.  We use these internally as measures of operational performance and disclose them externally to assist analysts, investors and lenders in their comparisons of operational performance, valuation and debt capacity across companies with differing capital, tax and legal structures. We believe the investment community frequently uses these measures in the evaluation of similarly situated companies. Adjusted EBITDA is also used by the Company as a factor to determine the total amount of incentive compensation to be awarded to executive officers and other employees.  EBITDA, Adjusted EBITDA, Adjusted EPS and Net Leverage Ratio, however, are not measures of financial performance under accounting principles generally accepted in the United States of America (“GAAP”) and should not be considered as alternatives to, or more meaningful than, net income as measures of operating performance or to cash flows from operating, investing or financing activities or as measures of liquidity. Since EBITDA, Adjusted EBITDA, Adjusted EPS and Net Leverage Ratio are not measures determined in accordance with GAAP and are thus susceptible to varying interpretations and calculations, these measures, as presented, may not be comparable to other similarly titled measures of other companies. EBITDA and Adjusted EBITDA do not represent amounts of funds that are available for management’s discretionary use. EBITDA and Adjusted EBITDA presented may not be the same as EBITDA and Adjusted EBITDA calculations as defined in the First Lien Credit Facilities.

Agiliti, Inc. and Subsidiaries

Adjusted EBITDA

(unaudited)

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

(in thousands)

2021

2020

    

2021

2020

Net income (loss) attributable to Agiliti, Inc. and Subsidiaries

$

9,668

$

(10,208)

$

14,023

$

(22,008)

Interest expense

10,711

13,560

 

40,444

 

46,532

Income tax expense (benefit)

7,943

(573)

 

13,832

 

(5,678)

Depreciation and amortization

46,860

42,597

 

138,676

 

124,659

EBITDA

75,183

45,376

206,975

143,505

Non-cash share-based compensation expense

4,360

3,206

10,127

7,657

Management and other expenses (1)

(3,266)

7,626

(256)

Transaction costs (2)

2,189

1,137

6,440

1,699

Tax receivable agreement remeasurement

197

9,600

4,542

9,600

Loss on extinguishment of debt (3)

10,116

Adjusted EBITDA

$

81,929

$

56,053

$

245,826

$

162,205


(1) Management and other expenses represent (a) management fees and buyout termination fee under the Advisory Services Agreement, which was terminated in connection with the initial public offering and (b) employee related non-recurring expenses.

(2) Transaction costs represent costs associated with potential and completed mergers and acquisitions and are primarily related to the Northfield acquisition for the nine months ended September 30, 2021.

(3) Loss on extinguishment of debt consists of the write-off of the unamortized deferred financing costs and debt discount and an additional 1% redemption price related to the repayment of our Second Lien Term Loan and the write-off of the unamortized deferred financing costs related to the amendment of our Revolving Credit Facility.


Agiliti, Inc. and Subsidiaries

Non-GAAP Financial Measure: Adjusted EPS

(unaudited)

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

(in thousands)

2021

2020

    

2021

2020

Net income (loss) attributable to Agiliti, Inc. and Subsidiaries

$

9,668

$

(10,208)

$

14,023

$

(22,008)

Amortization

 

21,497

 

17,558

 

60,427

 

51,702

Non-cash share-based compensation expense

 

4,360

 

3,206

 

10,127

 

7,657

Management and other expenses (1)

 

 

(3,266)

 

7,626

 

(256)

Transaction costs (2)

 

2,189

 

1,137

 

6,440

 

1,699

Tax receivable agreement remeasurement (3)

 

197

 

9,600

 

4,542

 

9,600

Loss on extinguishment of debt (4)

10,116

Income tax benefit associated with pre-tax adjustments (5)

 

(6,724)

 

(4,733)

 

(20,452)

 

(15,527)

Adjusted Net Income

$

31,187

$

13,294

$

92,849

$

32,867

Weighted average shares outstanding - diluted

 

138,491

 

103,706

 

125,515

 

103,680

Adjusted EPS

$

0.23

$

0.13

$

0.74

$

0.32


(1) Management and other expenses represent (a) management fees and buyout termination fee under the Advisory Services Agreement, which was  terminated in connection with the initial public offering and (b) employee related non-recurring expenses. (2) Transaction costs represent costs associated with potential and completed mergers and acquisitions and are primarily related to the Northfield  acquisition for the nine months ended September 30, 2021. (3) Tax receivable agreement remeasurement represents the change in the fair value of the tax receivable agreement. (4) Loss on extinguishment of debt consists of the write-off of the unamortized deferred financing costs and debt discount and an additional 1% redemption price related to the repayment of our Second Lien Term Loan and the write-off of the unamortized deferred financing costs related to the amendment of our Revolving Credit Facility. (5) Income tax benefit associated with pre-tax adjustments represents the tax benefit or provision associated with the reconciling items between net income (loss) and Adjusted Net Income.  To determine the aggregate tax effect of the reconciling items, we utilized statutory income tax rates ranging from 0% to 26%, depending upon the applicable jurisdictions of each adjustment.


Agiliti, Inc. and Subsidiaries

Non-GAAP Financial Measure: Net Leverage Ratio

(unaudited)

September 30, 

(in millions)

2021

Term Loan B (due 2026)

$

1,035.4

Consolidated Capital Leases

26.1

Less: Deferred Financing Fees

(17.1)

Debt

$

1,044.4

Less: Cash

(123.7)

Net Debt

$

920.7

LTM Adjusted EBITDA

$

317.8

Net Leverage

2.9x


EX-101.SCH 3 agti-20211109.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 agti-20211109_lab.xml EX-101.LAB EX-101.PRE 5 agti-20211109_pre.xml EX-101.PRE XML 6 agti-20211109x8k_htm.xml IDEA: XBRL DOCUMENT 0001749704 2021-11-09 2021-11-09 AGILITI, INC. \DE 0001749704 false 8-K 2021-11-09 DE 001-40361 83-1608463 6625 West 78th Street Suite 300 Minneapolis MN 55439 952 893-3200 false false false false Common Stock, par value $0.0001 AGTI NYSE false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Nov. 09, 2021
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Nov. 09, 2021
Entity File Number 001-40361
Entity Registrant Name AGILITI, INC. \DE
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 83-1608463
Entity Address, Address Line One 6625 West 78th Street
Entity Address, Adress Line Two Suite 300
Entity Address, City or Town Minneapolis
Entity Address, State or Province MN
Entity Address, Postal Zip Code 55439
City Area Code 952
Local Phone Number 893-3200
Title of 12(b) Security Common Stock, par value $0.0001
Trading Symbol AGTI
Security Exchange Name NYSE
Entity Emerging Growth Company false
Entity Emerging Growth Company false
Entity Central Index Key 0001749704
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Amendment Flag false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.agilitihealth.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports agti-20211109x8k.htm agti-20211109.xsd agti-20211109_lab.xml agti-20211109_pre.xml agti-20211109xex99d1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "agti-20211109x8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "agti-20211109x8k.htm" ] }, "labelLink": { "local": [ "agti-20211109_lab.xml" ] }, "presentationLink": { "local": [ "agti-20211109_pre.xml" ] }, "schema": { "local": [ "agti-20211109.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "agti", "nsuri": "http://www.agilitihealth.com/20211109", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "agti-20211109x8k.htm", "contextRef": "Duration_11_9_2021_To_11_9_2021_z7eKjuTmL0-nYoXk7uEIrQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.agilitihealth.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "agti-20211109x8k.htm", "contextRef": "Duration_11_9_2021_To_11_9_2021_z7eKjuTmL0-nYoXk7uEIrQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilitihealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilitihealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilitihealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilitihealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilitihealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Adress Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilitihealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilitihealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilitihealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilitihealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilitihealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilitihealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilitihealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilitihealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilitihealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilitihealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilitihealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilitihealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilitihealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilitihealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilitihealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilitihealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilitihealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.agilitihealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001558370-21-015302-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-21-015302-xbrl.zip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�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end